GENE ONLINE|News &
Opinion
Blog

2021-08-02| PartnerM&ASpecial

A Boom in High-Value M&A and Licensing Deals in the Exosome Field

by GeneOnline
Share To
During the pandemic, the growth of most biopharma businesses had slowed down, except for COVID-19 vaccines and therapies. Yet, exosome-related deals have thrived even under such difficult circumstances, shedding light on the tremendous potential of startups and ground-breaking technologies.  Who are the buyers? And who are the rising stars?

Exosome as IVD: M&A
The most significant med-tech application of exosomes is the ExoDx Prostate Test (EPI), developed by Exosome Diagnostics Inc. (Exosome Dx), now part of Bio-Techne Corp. (NASDAQ: TECH).
EPI, the first exosome-based liquid biopsy test to receive FDA breakthrough

GO Prime with only $1.49 now

LATEST
Ginkgo Bioworks and Pfizer Forge $331 Million Collaboration for RNA-Based Drug Discovery
2023-09-29
Johnson & Johnson Partners with Singapore to Boost Life Sciences Innovation
2023-09-28
Vietnam and South Korea Strengthen Cooperation in Multiple Sectors
2023-09-27
PeptiDream and Genentech Collaborate on Novel Peptide-Radioisotope Drug Conjugates
2023-09-27
AcuraStem and Takeda Collaborate on Innovative ALS Treatment
2023-09-27
Seven AI/ML for Life Sciences Companies Identified as Innovators in New Clarivate Companies to Watch Report
2023-09-27
GeneOnline’s Weekly News Highlights: Sept 17-Sept 22
2023-09-26
EVENT
2023-10-04
BioFuture 2023
New York city,USA
Scroll to Top